JP6914269B2 - Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法 - Google Patents

Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法 Download PDF

Info

Publication number
JP6914269B2
JP6914269B2 JP2018548001A JP2018548001A JP6914269B2 JP 6914269 B2 JP6914269 B2 JP 6914269B2 JP 2018548001 A JP2018548001 A JP 2018548001A JP 2018548001 A JP2018548001 A JP 2018548001A JP 6914269 B2 JP6914269 B2 JP 6914269B2
Authority
JP
Japan
Prior art keywords
aimp2
cancer
hsp70
binding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018548001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512693A5 (enExample
JP2019512693A (ja
Inventor
キム、スンフン
ギュ キム、テ
ギュ キム、テ
リム、セミ
Original Assignee
メディシナル バイオコンバージェンス リサーチ センター
メディシナル バイオコンバージェンス リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディシナル バイオコンバージェンス リサーチ センター, メディシナル バイオコンバージェンス リサーチ センター filed Critical メディシナル バイオコンバージェンス リサーチ センター
Publication of JP2019512693A publication Critical patent/JP2019512693A/ja
Publication of JP2019512693A5 publication Critical patent/JP2019512693A5/ja
Application granted granted Critical
Publication of JP6914269B2 publication Critical patent/JP6914269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018548001A 2016-03-07 2017-03-07 Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法 Active JP6914269B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0027077 2016-03-07
KR1020160027077A KR102297505B1 (ko) 2016-03-07 2016-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
PCT/KR2017/002442 WO2017155277A1 (ko) 2016-03-07 2017-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법

Publications (3)

Publication Number Publication Date
JP2019512693A JP2019512693A (ja) 2019-05-16
JP2019512693A5 JP2019512693A5 (enExample) 2020-06-18
JP6914269B2 true JP6914269B2 (ja) 2021-08-04

Family

ID=59790548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548001A Active JP6914269B2 (ja) 2016-03-07 2017-03-07 Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法

Country Status (6)

Country Link
US (1) US11442057B2 (enExample)
EP (1) EP3418739B1 (enExample)
JP (1) JP6914269B2 (enExample)
KR (1) KR102297505B1 (enExample)
CN (1) CN109073638B (enExample)
WO (1) WO2017155277A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101831435B1 (ko) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2 단백질에 특이적으로 결합하는 항체
US11758948B2 (en) 2018-01-29 2023-09-19 Altria Client Services Llc Lighting unit for aerosol-generating systems
RU2764430C1 (ru) 2018-01-29 2022-01-17 Филип Моррис Продактс С.А. Блок подсветки для систем, генерирующих аэрозоль
KR102308134B1 (ko) 2018-04-26 2021-10-01 재단법인 의약바이오컨버젼스연구단 mTOR 저해제로서의 신규 화합물 및 이의 용도
CN117769431A (zh) * 2021-03-30 2024-03-26 德克萨斯大学体系董事会 瓜氨酸化蛋白作为用于癌症的生物标志物和疗法靶
CN115786504B (zh) * 2022-08-31 2023-09-19 中国人民解放军总医院京南医疗区 Hspa4抑制剂在治疗黑素瘤中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US8003780B2 (en) 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
KR20060057992A (ko) * 2004-11-24 2006-05-29 재단법인서울대학교산학협력재단 ｐ38-ＤＸ2 및 이의 용도
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
KR20070113926A (ko) * 2006-05-26 2007-11-29 재단법인서울대학교산학협력재단 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
KR101067816B1 (ko) * 2007-11-09 2011-09-27 (주)네오믹스 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
CN102985103A (zh) * 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
WO2013006076A1 (en) * 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases
KR20130016041A (ko) * 2011-08-04 2013-02-14 재단법인 의약바이오컨버젼스연구단 신규한 아닐린 유도체 및 이의 용도
KR101500804B1 (ko) * 2012-04-20 2015-03-11 단국대학교 산학협력단 Ａｉｍｐ２ 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
KR101464360B1 (ko) * 2012-11-09 2014-11-21 주식회사 대웅 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물
KR101577315B1 (ko) 2013-03-14 2015-12-15 부산대학교 산학협력단 AIMP2-DX2와 p14/ARF의 상호작용을 이용한 암 치료제의 스크리닝 방법
KR101762433B1 (ko) * 2013-06-05 2017-07-28 재단법인 의약바이오컨버젼스연구단 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
KR101514320B1 (ko) * 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
KR101621963B1 (ko) * 2014-03-06 2016-05-17 한국과학기술원 Aimp2의 엑손2 결손체 돌연변이 검출용 분자신호기 및 이를 이용한 aimp2 돌연변이의 검출방법
EP3162803B1 (en) * 2014-06-30 2019-09-11 Pusan National University Industry-University Cooperation Foundation New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient

Also Published As

Publication number Publication date
US11442057B2 (en) 2022-09-13
CN109073638B (zh) 2022-04-26
EP3418739B1 (en) 2021-05-12
CN109073638A (zh) 2018-12-21
KR20170104263A (ko) 2017-09-15
WO2017155277A1 (ko) 2017-09-14
US20190033295A1 (en) 2019-01-31
WO2017155277A8 (ko) 2018-11-08
EP3418739A4 (en) 2019-03-06
KR102297505B1 (ko) 2021-09-01
JP2019512693A (ja) 2019-05-16
EP3418739A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
JP6914269B2 (ja) Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法
Meng et al. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma
Lagadec et al. Radiation-induced Notch signaling in breast cancer stem cells
Lu et al. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells
Zhou et al. Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC
Chen et al. Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid
Tang et al. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/β-catenin positive feedback loop
US9597369B2 (en) Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
Cai et al. Overexpression of caveolin‐1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells
Gong et al. Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death
Zhao et al. Noxa and Puma genes regulated by hTERT promoter can mitigate growth and induce apoptosis in hepatocellular carcinoma mouse model
EP2857392A1 (en) Small compound targeting at tacc3
Zhu et al. Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant‐dependent manner
KR101367832B1 (ko) 종양 억제 타겟으로서 Ｈａｄｅｓ의 용도
EP3801473B1 (en) Setbp1 inhibitors for the treatment of myeloid neoplasms and solid tumors
Wang et al. RGS-GAIP–interacting protein controls breast cancer progression
Mrozek et al. Anti-cancer small-molecule Inauhzin-C confines its cytotoxicity to cancer cells by targeting GRP78
Ludwig et al. The tumor suppressor, p190RhoGAP, differentially initiates apoptosis and confers docetaxel sensitivity to breast cancer cells
Jia et al. Raddeanin A (RA) Inhibited EMT and Stemness in Glioblastoma via downregulating Skp2
Fan et al. High-fat diet promotes colorectal carcinogenesis through SERCA2 mediated serine phosphorylation of Annexin A2
Miao et al. A Small Molecule Selectively Targets N-Myc to Suppress Neuroblastoma Cancer Progression
CN119925343B (zh) squamocin的新应用
CN115590945B (zh) 一种用于治疗肿瘤的多肽及其应用
JP7638527B2 (ja) 性ホルモン非感受性ｇｒｅｂ１陽性腫瘍の治療剤
KR100880850B1 (ko) 고형암 세포에서 사이클로필린 ａ의 발현을 억제하는물질을 포함하는 시스플라틴에 대한 내성 억제용 약제학적조성물 및 그를 이용하여 고형암의 시스플라틴에 대한내성을 억제하는 방법

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210713

R150 Certificate of patent or registration of utility model

Ref document number: 6914269

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250